QuidelOrtho Corp (QDEL) Form 10-Q — Aug 6, 2026
QuidelOrtho reported Q2 fiscal 2026 revenue of $630.9 million, up 3% year over year, with the net loss narrowing to $92.9 million (-$1.36 per share) from $255.4 million a year earlier. Labs and Point of Care drove the quarter, with Point of Care revenue up 16% on stronger respiratory demand. First-half revenue still fell 4% to $1,250.7 million, hurt by the terminated Grifols Joint Business, slower distributor sales in China ahead of new IVD pricing guidelines, and the now-substantially completed wind-down of the U.S. donor screening portfolio.
Key figures
- Eps
- -$1.36 Q2 FY2026 (vs -$3.77); -$2.71 H1 FY2026 (vs -$3.97)
- Revenue
- $630.9M Q2 FY2026 (+3% YoY); $1,250.7M H1 FY2026 (-4% YoY)
- Net Income
- -$92.9M Q2 FY2026; -$184.7M H1 FY2026
- Cash Position
- 123.4
- Shares Outstanding
- 68575427
- Optimization Plan
- ~$100M cumulative pre-tax charges through 2027; $28.1M incurred to date; ~$50M targeted net savings
- Operating Cash Flow
- -$143.6M H1 FY2026 vs +$18.8M prior-year H1
- Grifols Termination
- $65.0M charge recorded in FY2025; $25M paid during Q2 FY2026
- Interest Expense Net
- $54.7M Q2 FY2026 vs $40.5M prior-year Q2; $105.8M H1 FY2026
- China Segment Revenue
- $67.8M Q2 FY2026, down 19% YoY
- Revolver Availability
- $426.5M as of June 28, 2026
- Term Loan Effective Rates
- Term Loan A 6.86%; Term Loan B 8.43%
- Respiratory Revenue Share
- 8% of Q2 and 9% of H1 FY2026 total revenues
- Lex Diagnostics Consideration
- $174.6M total ($98.6M cash, $41.0M carry-over equity basis, $35.0M contingent consideration)
- Weighted Avg Effective Interest Rate
- 6.97% on aggregate Term Loans, net of swaps
Price after filing
Close on the filing date to close N calendar days later (from $17.58). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.